BridgeBio Oncology Therapeutics, Inc. BBOT
BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT) is an oncology drug developer. Its lead program, BBO-8520, is in Phase 1 for KRAS G12C-mutated non-small cell lung cancer. Its next catalyst on record is BBO-8520: Updated Phase 1 clinical data (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: BBO-8520 — Updated Phase 1 clinical data (H2 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| BBO-8520 | KRAS G12C-mutant NSCLC (single agent and with pembrolizumab) | small molecule | Phase 1 |
| BBO-11818 | KRAS-mutant solid tumors incl. PDAC | small molecule | Phase 1 |
| BBO-10203 | HER2+ and HR+/HER2- breast cancer, KRAS-mutant colorectal cancer and NSCLC | small molecule | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.